FBInvestor
Funds / Braidwell LP
Institutional Fund

Braidwell LP

Stamford, CTCIK 19209385 filings on record

Portfolio Value
$2.63B
Q1 2026
Holdings
82
Reported positions
New Buys
28
Opened this quarter
QoQ Change
+0.6%
from $2.61B

Portfolio Value Trend

Reported 13F value by quarter

Portfolio value trend — upgrade to see history

Upgrade

Top Allocations

Largest positions by weight

  • Caris Life Sciences Inc5.5%
  • Neurocrine Biosciences Inc3.3%
  • Glaukos Corp3.1%
  • Centessa Pharmaceuticals PLC3.0%
  • Xenon Pharmaceuticals Inc3.0%
  • Dianthus Therapeutics Inc2.9%
  • Other79.3%

Portfolio Holdings

82 positions · Q1 2026

#SecuritySharesValue% Port.Δ SharesActivity
1Caris Life Sciences Inc8.01M$143.21M5.5%+193.3KAdded
2Neurocrine Biosciences Inc652.1K$85.91M3.3%99.4KReduced
3Glaukos Corp763.5K$82.20M3.1%158.5KReduced
4Centessa Pharmaceuticals PLC1.99M$78.91M3.0%201.6KReduced
5Xenon Pharmaceuticals Inc1.34M$77.83M3.0%486.6KReduced
6Dianthus Therapeutics Inc899.4K$75.47M2.9%374.6KReduced
7Edgewise Therapeutics Inc2.35M$73.95M2.8%2.86MReduced
8Irhythm Technologies Inc610.2K$72.01M2.7%+392.8KAdded
9Nuvalent Inc700.4K$71.76M2.7%121.0KReduced
10Kodiak Sciences Inc1.82M$69.33M2.6%254.1KReduced

72 more holdings on Premium

See this fund's complete portfolio, full position changes, and activity history.

Unlock full portfolio